Molecular structure of LY293111, CAS Number: 161172-51-6
LY293111 (CAS 161172-51-6)
Alternate Names:
VML 295; Etalocib
Application:
LY293111 is a P2Y7 (leukotrine B4 repector, BLT1) antagonist
CAS Number:
161172-51-6
Molecular Weight:
544.61
Molecular Formula:
C33H33FO6
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY293111 is a potent antagonist of P2Y7 (leukotrine B4 repector, BLT1) which inhibits the specific binding of radiolabeled-LTB4 to this receptor (IC50 = 17.6 nM). This further prevents LTB4-induced chemotaxis of neutrophils (IC50 = 6.3 nM). Additional in vitro studies have shown that LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 cell lines and subcutaneous xenografts by inducing apoptosis and S-phase arrest.
LY293111 (CAS 161172-51-6) References
- Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies. | Silbaugh, SA., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 361: 397-404. PMID: 10763854
- Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. | Tong, WG., et al. 2002. Clin Cancer Res. 8: 3232-42. PMID: 12374694
- Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats. | Perkins, EJ., et al. 2003. Drug Metab Dispos. 31: 1382-90. PMID: 14570771
- Effect of LY293111 in combination with gemcitabine in colonic cancer. | Hennig, R., et al. 2004. Cancer Lett. 210: 41-6. PMID: 15172119
- A novel anti-pancreatic cancer agent, LY293111. | Ding, XZ., et al. 2005. Anticancer Drugs. 16: 467-73. PMID: 15846111
- LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. | Hennig, R., et al. 2005. Neoplasia. 7: 417-25. PMID: 15967119
- Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. | Zhang, W., et al. 2005. Leukemia. 19: 1977-84. PMID: 16151469
- The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. | Adrian, TE., et al. 2008. PPAR Res. 2008: 827096. PMID: 19190780
- Leukotriene receptor antagonists, LY293111 and ONO-1078, protect neurons from the sPLA2-IB-induced neuronal cell death independently of blocking their receptors. | Yagami, T., et al. 2013. Neurochem Int. 63: 163-71. PMID: 23792223
- Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia. | Yektaei-Karin, E., et al. 2017. Leuk Lymphoma. 58: 1903-1913. PMID: 27931141
- RvE1 uses the LTB4 receptor BLT1 to increase [Ca2+]i and stimulate mucin secretion in cultured rat and human conjunctival goblet cells. | Yang, M., et al. 2020. Ocul Surf. 18: 470-482. PMID: 32361084
- Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist. | Marder, P., et al. 1995. Biochem Pharmacol. 49: 1683-90. PMID: 7786309
- Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies. | Jackson, WT., et al. 1999. J Pharmacol Exp Ther. 288: 286-94. PMID: 9862783
Inhibitor of:
GPR-44, LF, LT-β, LTB4R2, P2Y7, and PAFAH1B2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY293111, 500 µg | sc-221866 | 500 µg | $141.00 | |||
LY293111, 1 mg | sc-221866A | 1 mg | $347.00 |